Adding Rituximab to Short Intensive Chemo Improves EFS in Burkitt Lymphoma

Share this content:
The addition of rituximab to a short intensive chemotherapy regimen improved event-free survival in adult patients with Burkitt lymphoma or leukemia.
The addition of rituximab to a short intensive chemotherapy regimen improved event-free survival in adult patients with Burkitt lymphoma or leukemia.

The addition of rituximab to a short intensive chemotherapy regimen improved event-free survival in adult patients with Burkitt lymphoma or leukemia, a study published in the journal The Lancet has shown.1

Burkitt lymphoma is a type of high-grade non-Hodgkin lymphoma that develops from B cells and is one of the fastest growing lymphomas. The standard of care for adults with Burkitt lymphoma or leukemia is short intensive chemotherapy, but single-arm studies have suggested that the addition of rituximab to these regimens may improve patient outcomes. Therefore, researchers sought to evaluate the addition of rituximab in a randomized, controlled trial.

For the open-label, phase 3 trial, researchers enrolled 260 adult patients with untreated HIV-negative Burkitt lymphoma or leukemia. Patients were stratified into 2 groups based on the absence (group B) or presence (group C) of bone marrow or central nervous system involvement. Patients were further stratified in group C with respect to age (< 40 years, 40 to 60 years, and > 60 years) and central nervous system involvement.

Participants were randomly assigned in each group to receive either rituximab 375 mg/m2 intravenously on days 1 and 6 during the first 2 courses of chemotherapy for a total of 4 infusions plus chemotherapy or chemotherapy alone.

Results showed that with a median follow-up of 38 months, patients who received rituximab achieved a 3-year event-free survival of 75% (95% CI, 66 - 82) compared with 62% (95% CI, 53 - 70) for the chemotherapy alone group (HR, 0.59; 95% CI, 0.38 - 0.94; P = .025).

RELATED: Anti-CD19 CAR T-Cells Safe for Refractory Aggressive Non-Hodgkin Lymphoma

In terms of safety, adverse events did not significantly differ between the 2 treatment arms. The most common adverse events were infectious and hematologic in nature.

Reference

  1. Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial [published online ahead of print April 11, 2016]. Lancet. doi: 10.1016/S0140-6736(15)01317-3.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters